Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200-Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.66. Xtant Medical shares last traded at $0.65, with a volume of 7,652 shares traded.

Wall Street Analysts Forecast Growth

Separately, BTIG Research lifted their price target on Xtant Medical from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.

Xtant Medical Stock Performance

The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.98 and a current ratio of 2.34. The stock has a market capitalization of $85.31 million, a P/E ratio of -65.49 and a beta of 0.38.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($0.03) EPS for the quarter. Xtant Medical had a negative return on equity of 3.60% and a negative net margin of 1.64%. The company had revenue of $27.87 million during the quarter.

Institutional Trading of Xtant Medical

A hedge fund recently bought a new stake in Xtant Medical stock. Juniper Investment Company LLC purchased a new stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 348,399 shares of the medical device company’s stock, valued at approximately $408,000. Xtant Medical comprises approximately 0.2% of Juniper Investment Company LLC’s portfolio, making the stock its 10th largest holding. Juniper Investment Company LLC owned 0.27% of Xtant Medical as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.